ArticleCancer discovery2023

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.

Ryan J Hartmaier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.